An oral preparation containing progestin and its preparation method and application
An oral preparation with reduced benzyl benzoate content, using propylene glycol monocaprylate and PEG35 castor oil, addresses safety concerns and improves stability and bioavailability, enhancing the clinical and commercial value of 17-α hydroxyprogesterone caproate formulations.
Patent Information
- Application Number
- CN202111306285.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-05
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-11-05
AI Technical Summary
Existing 17-α hydroxyprogesterone caproate oral preparations face challenges due to the use of benzyl benzoate as a solvent, which has safety concerns and limited acceptable daily intake, hindering their widespread use and promotion.
Development of an oral preparation with reduced or no benzyl benzoate, utilizing excipients such as propylene glycol monocaprylate, PEG35 castor oil, and propylene glycol monolaurate to ensure high safety, stability, and bioavailability, with specific weight percentages of these components.
The new formulation achieves enhanced safety, stability, and bioavailability, reducing the daily intake of benzyl benzoate to safe levels, increasing clinical and commercial application value, and potentially lowering the dosage required.
Smart Images

Figure CN116077416B_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of pharmaceutical preparations. Specifically, the present application provides an oral preparation containing progestogen, a preparation method and an application thereof, wherein the preparation does not contain or contains only a low level of benzyl benzoate. Background Art
[0002] Progestogens include progesterone, norethisterone, norgestrel, 17-α hydroxyprogesterone, etc. They have rich and diverse physiological functions in the human body. Currently, 17-α hydroxyprogesterone has been used for contraception, treatment of miscarriage, menstrual disorders, uterine bleeding, breast cancer and other diseases. In addition, the applicant has also discovered that 17-α hydroxyprogesterone caproate has the effect of treating cytokine storm syndrome and has applied for a patent for this.
[0003] Oral preparations are significantly superior to injections and other dosage forms in terms of ease of use and compliance. The applicant has previously developed and patented an oral preparation of 17-α hydroxyprogesterone caproate in cooperation with other entities. The preparation has good oral availability and stability. However, the preparation uses benzyl benzoate as the main solvent component, and the safety of benzyl benzoate to the human body has not been clearly studied. In the regulations of the Joint Expert Committee on Food Additives (JECFA) under the Food and Agriculture Organization of the United Nations and the World Health Organization, the acceptable daily intake (ADI) of benzyl benzoate expressed in benzoic acid equivalents is limited to 5 mg / kg.
[0004] The above problems make it difficult for the existing 17-α hydroxyprogesterone caproate oral preparations to be further promoted and used. Therefore, it is necessary to develop safer 17-α hydroxyprogesterone caproate oral preparations with low or no benzyl benzoate. Summary of the invention
[0005] To solve the above problems, the applicant screened a large number of excipients in terms of basic properties and safety, and designed an oral preparation with high safety, good stability, dissolution performance and bioavailability.
[0006] In one aspect, the present application provides an oral preparation containing a progestogen, characterized in that the oral preparation contains no or only a low level of benzyl benzoate.
[0007] Furthermore, the progestogen is 17-α hydroxyprogesterone caproate.
[0008] Furthermore, the weight percentage of benzyl benzoate in the oral preparation is less than 8%; preferably, less than 7%; more preferably, less than 6%; and even more preferably, less than 5%.
[0009] Furthermore, the weight percentage of benzyl benzoate in the oral preparation is less than 4%; preferably, less than 3%; more preferably, less than 2%; and even more preferably, less than 1%.
[0010] Furthermore, the oral preparation does not contain benzyl benzoate.
[0011] Furthermore, the oral preparation comprises propylene glycol monocaprylate, preferably Capryol® 90.
[0012] Furthermore, the oral preparation contains 40-60% by weight, preferably 45-55% by weight, more preferably 50-52% by weight, and even more preferably 51.85% by weight of propylene glycol monocaprylate.
[0013] Furthermore, the oral preparation comprises PEG35 castor oil, preferably Kolliphor® ELP.
[0014] Furthermore, the oral preparation contains 5-10% by weight, preferably 6-9% by weight, more preferably 7-8% by weight, and even more preferably 7.65% by weight of PEG35 castor oil.
[0015] Furthermore, the weight percentage of progesterone in the oral preparation is 10-20%; preferably, 12-18%; more preferably, 15-17.5%.
[0016] Furthermore, the oral preparation comprises propylene glycol monolaurate, preferably Lauroglycol® 90.
[0017] Furthermore, the oral preparation contains 15-30% by weight of propylene glycol monolaurate, preferably 20-25% by weight of propylene glycol monolaurate, more preferably 20.8%-20.9% by weight of propylene glycol monolaurate, and most preferably 20.83% by weight of propylene glycol monolaurate.
[0018] Furthermore, the oral preparation comprises glyceryl monocaprylate, preferably Capmul 808G.
[0019] Furthermore, the oral preparation contains 5-25% by weight, preferably 8-22% by weight of glyceryl monocaprylate.
[0020] Furthermore, the oral preparation contains 17-α hydroxyprogesterone caproate, propylene glycol monocaprylate, PEG35 castor oil, benzyl benzoate, and propylene glycol monolaurate or glyceryl monocaprylate.
[0021] Furthermore, the oral preparation contains 10-20% by weight of 17-α hydroxyprogesterone caproate, 45-55% by weight of propylene glycol monocaprylate, 5-10% by weight of PEG35 castor oil, 1-6% by weight of benzyl benzoate, 15-25% by weight of propylene glycol monolaurate or 9-22% by weight of glyceryl monocaprylate.
[0022] Furthermore, the oral preparation is composed of 15% by weight of 17-α hydroxyprogesterone caproate, 51.8%-51.9% of propylene glycol monocaprylate (preferably 51.85% of propylene glycol monocaprylate), 7.65% of PEG35 castor oil, 4.6-4.7% of benzyl benzoate (preferably 4.675% of benzyl benzoate), and 20.8-20.9% of propylene glycol monolaurate (preferably 20.825% of propylene glycol monolaurate).
[0023] or composed of 17.5% 17-alpha hydroxyprogesterone caproate, 60.64% propylene glycol monocaprylate, 7.43% PEG35 castor oil, 5.355% benzyl benzoate, 9.075% glyceryl monocaprylate;
[0024] Alternatively, it is composed of 15% 17-alpha hydroxyprogesterone caproate, 51.8%-51.9% propylene glycol monocaprylate (preferably 51.85% propylene glycol monocaprylate), 7.65% PEG35 castor oil, 4.6-47% benzyl benzoate (preferably 4.675% benzyl benzoate), and 20.8-20.9% glyceryl monocaprylate (preferably 20.825% glyceryl monocaprylate).
[0025] Furthermore, the oral preparation contains 17-α hydroxyprogesterone caproate, propylene glycol monocaprylate, PEG35 castor oil, and propylene glycol monolaurate.
[0026] Furthermore, the oral preparation contains 10-20% by weight of 17-α hydroxyprogesterone caproate, 45-55% by weight of propylene glycol monocaprylate, 5-10% by weight of PEG35 castor oil, and 20-30% by weight of propylene glycol monolaurate.
[0027] Furthermore, the oral preparation is composed of 15% by weight of 17-α hydroxyprogesterone caproate, 51.85% by weight of propylene glycol monocaprylate, 7.65% by weight of PEG35 castor oil, and 25.50% by weight of propylene glycol monolaurate.
[0028] Furthermore, the oral preparation of the present application is in the form of oral liquid or soft capsule, preferably in the form of soft capsule.
[0029] Furthermore, the unit preparation contains 80-150 mg, preferably 100-120 mg, of progestogen.
[0030] Furthermore, the oral preparation is used for contraception, or for treating miscarriage, irregular menstruation, uterine bleeding, breast cancer, and cytokine storm syndrome.
[0031] On the other hand, the present application provides a method for preparing the above-mentioned oral preparation, comprising the steps of weighing excipients, pre-dissolving excipients, mixing excipients, adding progesterone, and dissolving progesterone.
[0032] On the other hand, the present application provides the use of the above-mentioned oral preparation in the preparation of drugs or reagents for contraception, treatment of miscarriage, irregular menstruation, uterine bleeding, breast cancer, and cytokine storm syndrome.
[0033] On the other hand, the present application provides a method for contraception, treatment of miscarriage, irregular menstruation, uterine bleeding, breast cancer, and cytokine storm syndrome, characterized in that it includes the step of using the above-mentioned oral preparation.
[0034] In this application, 17-α hydroxyprogesterone caproate is also referred to as hydroxyprogesterone caproate, 17-HPC, 17-hydroxyprogesterone caproate, 17-hydroxyhexyprogesterone, hydroxyprogesterone caproate, etc., and its CAS number is 630-56-8; it is abbreviated as HPC in certain diagrams and schemes of the embodiments. The low level of benzyl benzoate described in this application means that when the preparation of this application is taken according to the dosage, the intake of benzyl benzoate (or benzoic acid equivalent) meets the recommended / required level of various countries, organizations or textbooks. Preferably, when the preparation of this application is taken according to the dosage, the intake of benzyl benzoate (or benzoic acid equivalent) is significantly lower than the recommended / required level of various countries, organizations or textbooks.
[0035] The trade names such as Capryol®90, Lauroglycol®90, Capmul 808G, Peceol®, Maisine®CC, Koliphor®HS15, Koliphor®ELP, Koliphor®RH40 listed in this application do not mean that the protection scope is limited to the trade name, and products with similar or same chemical composition and physicochemical properties are also within the protection scope of this application. In this regard, a non-limiting example is Capryol®90 used in the examples of this application, and those skilled in the art may also select other propylene glycol monocaprylate products according to needs and performance.
[0036] In addition to the aforementioned oral liquid and soft capsule dosage forms, other oral dosage forms containing the liquid preparation formula provided in this application are also within the scope of protection of this application.
[0037] In addition to the aforementioned indications, other known or researched diseases that can be treated with progesterone are also within the scope of protection for pharmaceutical use of this application.
[0038] According to the needs of treatment, the composition of the present invention does not exclude the presence of other known and unknown drugs for treating related diseases, or these drugs can be used in combination with the composition of the present application. These drugs include, but are not limited to, anti-inflammatory drugs, antipyretic drugs, anti-tumor drugs, immunomodulatory drugs, etc.
[0039] The present invention improves the chemical stability of the low benzyl benzoate oral preparation formula, and can enhance the clinical and commercial application scope and use value of the formula. The high chemical stability of the formula can reduce the production cost of the product, and can also reduce the storage and transportation costs of the product, so that the product has higher economic and commercial value.
[0040] The present invention improves the bioavailability of the low benzyl benzoate oral preparation formula, can reduce the dosage of the medicine, and enhance the practicality of the medicine use for patients. The experimental results show that the solubility of the low benzyl benzoate oral preparation formula in the water phase of the dissolution experiment is 8.8 times higher than that of the original high benzyl benzoate oral preparation formula in the experiment of simulating intestinal fluid without fasting, indicating that its bioavailability is 8.8 times higher than that of the original high benzyl benzoate oral preparation formula, so that its dosage can also be 8.8 times lower than that of the original high benzyl benzoate formula, which can greatly increase the clinical and commercial application value of the low benzyl benzoate formula.
[0041] The safety of the low benzyl benzoate formula of the present invention is also greatly improved compared with the original high benzyl benzoate formula. The auxiliary materials used in the low benzyl benzoate formula meet the requirements for safe use, and the daily amount of auxiliary materials used also meets the standards and requirements for safe use. This also greatly increases the scope of use and commercial value of the low benzyl benzoate formula medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 The actual pictures of the stability test of each preparation at 5°C for 72 hours;
[0043] Figure 2 The actual pictures of the stability test of each preparation at 12.5°C for 72 hours;
[0044] Figure 3 The actual pictures of the stability test of each preparation at 20°C for 72 hours;
[0045] Figure 4 The dissolution performance of 210106, 210112, and BB formulations in FaSSIF (full sample analysis);
[0046] Figure 5 The solubility performance of 210106, 210112, and BB formulations in FaSSIF (analysis of aqueous samples);
[0047] Figure 6 This is a real photo of the FaSSGF (simulated gastric fluid without food) solvent sample after 120 minutes of dissolution stirring;
[0048] Figure 7The dissolution performance of 210106, 210112, and BB formulations in FaSSGF (full sample analysis);
[0049] Figure 8 The solubility properties of 210106, 210112, and BB formulations in FaSSGF (analysis of aqueous samples);
[0050] Fig. 9 This is a real photo of the FeSSGF (fed intestinal simulation fluid) solvent sample after dissolution and stirring for 120 minutes;
[0051] Fig.10 The dissolution performance of 210106, 210112, and BB formulations in FeSSIF (whole sample analysis);
[0052] Fig.11 The solubility performance of formulations 210106, 210112, and BB in FeSSIF (analysis of aqueous samples);
[0053] Fig.12 Comparison of the dissolution performance of 210106 in FeSSIF, FaSSIF, and FaSSGF;
[0054] Fig.13 The dissolution performance of 210112 in FeSSIF, FaSSIF and FaSSGF is compared;
[0055] Fig.14 Comparison of the solubility performance of BB formula in FeSSIF, FaSSIF, and FaSSGF. DETAILED DESCRIPTION
[0056] Determination of the formula of Example 1
[0057] Through the screening of basic physical properties, toxicity and relevant standards, 10 kinds of auxiliary materials were screened out for formula development, including propylene glycol monocaprylate, propylene glycol monolaurate, monocaprylic glyceride, oleic glyceride, glyceryl monolinoleate, oleic acid, olive oil, PEG15 hydroxystearic acid, PEG35 castor oil, PEG40 hydrogenated castor oil. The above 10 auxiliary materials can be respectively the products sold under the trade names Capryol®90, Lauroglycol®90, Capmul 808G, Peceol®, Maisine®CC, oleic acid, olive oil, Koliphor®HS15, Kolliphor®ELP, Koliphor®RH40 listed in Table 1, or products of other brands can be used. The above trade names are only for clear description and are not used to limit the scope of the present invention.
[0058] First, the solubility properties of these excipients were studied: the basic results are shown in Table 1 below:
[0059] Table 117- Solubility of HPC in different excipients
[0060]
[0061] The data in Table 2 show that 17-HPC can achieve stable dissolution in the excipients propylene glycol monocaprylate, propylene glycol monolaurate, monocaprylic acid glyceryl, oleic acid glyceryl, glyceryl monolinoleate, oleic acid, and PEG35 castor oil, but the stable dissolution concentration in each excipient is different. For specific values, see the last column of Table 2. This study shows that 17-HPC cannot achieve a stable dissolution concentration in PEG15 hydroxystearic acid and PEG40 hydrogenated castor oil. The stable dissolution concentration of 17-HPC in olive oil cannot reach the meaningful dissolution concentration required for adult preparations.
[0062] Formulas 210104, 210106, 210108, 210110, 210112, and 210114 were designed based on the acceptable daily intake collected in the WHO-JECFA database or provided by the supplier, as well as the possible API dosage and drug dosage:
[0063] Table 2 Basic information of auxiliary materials
[0064]
[0065] Table 3 Oral formulations containing 17-HPC
[0066]
[0067] Note: ADI stands for Allowable daily intake, √ means met.
[0068] The table above shows that the selected 6 formulations all meet the safe intake amount. The experimental results show that except for formulations 1 and 6, the other 4 formulations can maintain physical stability when dispersed in the water phase without crystal precipitation. Therefore, further research is conducted on these 4 formulations.
[0069] The above formulas were screened to obtain the preferred formulas 210106, 210108, 210110, and 210112:
[0070] Table 4 Preferred oral formulations containing 17-HPC
[0071]
[0072] Example 2 Basic preparation process of the preparation
[0073] 50 g of each formulation was prepared by the following steps:
[0074] A. Weigh the required excipients (pre-dissolved) in a 100 mL bottle;
[0075] B. Mix the auxiliary materials under magnetic stirring (about 250RPM, 5 minutes);
[0076] C. Add the weighed amount of API (17-HPC);
[0077] D. Magnetic stirring, 250 RPM at room temperature, 1 hour; then 250 RPM in a 30°C warm bath, 3 hours;
[0078] E. Perform a test after dissolution is complete to ensure complete dissolution.
[0079] The preparation method of 210106 capsule preparation is as follows:
[0080] Step 1 - Filling Recipe Preparation
[0081] The container containing Kolliphor® ELP needs to be preheated to 50°C ± 5°C until it is completely molten and further homogenized before weighing.
[0082] All fill formulation preparation steps were performed under nitrogen flushing.
[0083] In a container, the required amounts of Capryol® 90 (2.593 kg), Lauroglycol® 90 (1.041 kg) and benzyl benzoate (0.234 kg) were mixed until homogenized at room temperature.
[0084] The required amount of 17-HPC drug substance (0.75 kg) was added and stirred thoroughly at 30°C ± 5°C until completely dissolved to obtain a clear solution without any suspended API particles.
[0085] The required amount of pre-melted Kolliphor® ELP (0.382 kg) will be added to the container and the complete formulation will be mixed with good stirring at 30°C ± 5°C until completely dissolved.
[0086] The formulation stored in a sealed container will be kept at 25°C ± 5°C with gentle stirring until completely degassed (i.e., a clear homogeneous solution without bubbles). The formulation will be stored at room temperature until packaging.
[0087] Table 5 Ingredients of capsule preparation
[0088]
[0089] Example 3 Physical stability at different temperatures
[0090] The stability of the preferred formulation was observed at different temperatures for 72 hours. The results are shown in Table 5.
[0091] The stability of the preferred formula was observed at different temperatures at different times. The results are shown in Table 6.
[0092] Table 6 Long-term (3 days, 2 weeks and 1 month) observation results of various preparations
[0093] Note:
[0094] Stable means that no crystalline deposits occur;
[0095] Less stable means very few deposits occur, such as 1-3 crystalline deposits;
[0096] Unstable means more crystalline deposits are present.
[0097] The results showed that all formulations were sensitive to low temperature (5 degrees Celsius), and 210106 was the only formulation that could remain stable at 12.5°C and 20°C for one month.
[0098] The results of the stability study of 210106 for a longer period of time (3 days, 2 weeks, 1 month, 2 months, 3 months, 4 months) are shown in Table 7:
[0099] Table 7 210106 Long-term (3 days, 2 weeks, 1 month, 2 months, 3 months, 4 months) observation results
[0100]
[0101] Note:
[0102] Stable means that no crystalline deposits occur;
[0103] Less stable means very few deposits occur, such as 1-3 crystalline deposits;
[0104] Unstable means more crystalline deposits are present.
[0105] Actual picture Figure 1-3 As shown:
[0106] Experimental Condition 5 o C, 72 hours: Only the leftmost formulation 106 showed no precipitation; the remaining three formulations all had precipitation to varying degrees.
[0107] Experimental conditions 12.5 oC, 72 hours; only the leftmost formulation 106 showed no precipitation; the remaining three formulations all had precipitation to varying degrees.
[0108] Experimental Condition 20 o C, 72 hours: The physical stability of the four formulations improved under the condition of elevated temperature. Formulations 106 (first from the left) and 110 (third from the left) showed no precipitation.
[0109] Example 4 Dissolution Experiment
[0110] Table 8 Experimental high BB / benzyl benzoate formula
[0111]
[0112] This formula is a formula previously developed by the applicant, which has good physical and chemical stability. However, due to the high content of benzyl benzoate, the relative safety of the formula needs to be improved, so the low benzyl benzoate formula included in this patent was developed. For the following dissolution experiment, the high benzyl benzoate formula (formula BB) and the low benzyl benzoate formula (formula 106 and formula 112) were compared in parallel.
[0113] method:
[0114] The dissolution apparatus is a Pion micro-dissolution apparatus, which is often used for formulation screening. This experiment evaluates the dissolution rate over time. Under non-sink conditions, the temperature is constant at 37°C, and 6 250 ml dissolution cups are used at 250 rpm with a magnetic stirring device. Since the dispersion is milky white, it is not applicable to evaluate the dissolution by UV spectroscopy (online analysis), and the solubility is tested by HPLC. The samples are divided into whole samples and aqueous samples. For comparative dissolution curves of different formulations, the same amount of API will be put into the same solvent volume: for example, 120 mg (i.e. 480 mg of BB formula and 800 mg of the newly developed formula are added to 250 mL of solvent. The sampling time points are as follows: T5 minutes, T15 minutes, T30 minutes, (T45 minutes), T60 minutes, T120 minutes.
[0115] FaSSIF (Fassinusitis Suppurative Intestinal Fluid)
[0116] The average value of each point in the dissolution curve is the average value of two dissolution cup tests. The complete sample is a 400µL sample of the solvent and 600µL of acetonitrile are added, and then analyzed by HPLC. The aqueous phase sample is a 1000µL sample of the solvent and centrifuged at 14.8 MRPM for 20 minutes. Then 400µL of the upper aqueous phase clear liquid is taken and 600µL of acetonitrile is added, and then analyzed by HPLC. The data are as follows:
[0117] Table 9 FaSSIF data
[0118]
[0119] Comparison of 210106 / 210112 / BB formulations in FaSSIF (FaSSIF dissolution medium, 37°C, 250RPM, manual sampling) Figure 4 (full sample analysis) and Figure 5 (Analysis of aqueous phase samples, centrifugation at 14.8MRPM for 20 minutes & supernatant sampling) As shown, all three formulations can reach a dissolution concentration close to 100% in about 5 minutes. Among them, the dissolution concentration of formulation 112 exceeded 100% at 5 minutes because the formulation dispersed slowly in the solvent, the sample was not uniform when sampling from the upper layer of the dissolution cup, and the inverted sample was more of the oil phase, so the concentration was too high. After a period of dissolution stirring, the concentration returned to about 100%. At the same time, according to the aqueous phase dissolution curve, we found that compared with the original BB formula, the two newly developed formulations had higher dissolution concentrations in the aqueous phase, indicating that the formulation showed higher API water solubility, especially the formulation prototype 210106; according to the experimental results and physical stability test results, the formulation prototype 210106 will be considered as the main formulation for in vivo preclinical experiments.
[0120] FaSSGF (FaSSGF)
[0121] The average value of each point in the dissolution curve is the average value of two dissolution cup tests. The complete sample is a 400µL sample of the solvent and 600µL of acetonitrile are added, and then analyzed by HPLC. The aqueous phase sample is a 1000µL sample of the solvent and centrifuged at 14.8 MRPM for 20 minutes. Then 400µL of the upper aqueous phase clear liquid is taken and 600µL of acetonitrile is added, and then analyzed by HPLC. The data are as follows:
[0122] Table 10 FaSSGF data
[0123]
[0124] Figure 6 This is a photo of the FaSSGF (unfed gastric fluid simulation fluid) solvent sample after 120 minutes of dissolution stirring. It can be seen that in the gastric fluid simulation fluid, the three formulations are all in a turbid suspension state, indicating that most of the API has not yet dissolved into the aqueous phase. This also explains the phenomenon of low solubility in the aqueous phase sample dissolution curve.
[0125] Comparison of 210106 / 210112 / BB formulations in FaSSGF (simulated gastric fluid without feeding) (FaSSGF dissolution medium, 37°C, 250RPM, manual sampling) Figure 7 (full sample analysis) and Figure 8 As shown in (Analysis of Aqueous Phase Samples), all three formulations can reach a dissolution concentration close to 100% in about 5 minutes. However, under the dissolution conditions of the aqueous gastric acid simulated solution, only a small amount of API can be dissolved in the aqueous phase. The three formulations are not much different under the dissolution conditions of the gastric acid simulated solution.
[0126] FeSSIF (Fed Intestinal Simulating Fluid)
[0127] The average value of each point in the dissolution curve is the average value of two dissolution cup tests. The complete sample is a 400µL sample of the solvent and 600µL of acetonitrile are added, and then analyzed by HPLC. The aqueous phase sample is a 1000µL sample of the solvent and centrifuged at 14.8 MRPM for 20 minutes. Then 400µL of the upper aqueous phase clear liquid is taken and 600µL of acetonitrile is added, and then analyzed by HPLC. The data are as follows:
[0128] Table 11 FeSSIF data
[0129]
[0130] Fig. 9 This is a photo of the FeSSGF (eating intestinal simulation fluid) solvent sample after 120 minutes of dissolution stirring. We can see that in the intestinal simulation fluid, the clarity of formula 106 and diazepam 112 is much higher than that of formula BB, indicating that most of the API has been dissolved in the water phase, so the turbidity is low. This also explains the phenomenon that the dissolution rate of formulas 106 and 102 in the water phase sample dissolution curve is much higher than that of formula BB.
[0131] Comparison of 210106 / 210112 / BB formulations in FeSSIF (FeSSIF dissolution medium, 37°C, 250RPM, manual sampling) Fig.10 (full sample analysis) and Fig.11(Analysis of aqueous samples) shows that all three formulations can reach a dissolution concentration close to 100% in about 5 minutes. At the same time, according to the aqueous dissolution curve, we found that compared with the original BB formula, the two newly developed formulations have a higher dissolution concentration in the aqueous phase, and this advantage exceeds the relative advantage of aqueous dissolution under FaSSIF (simulated intestinal fluid without food intake). The dissolution curve shows that the formulation exhibits a high API water solubility, especially the formulation prototype 210106; based on the experimental results and physical stability test results, the formulation prototype 210106 will be considered as the main formulation for in vivo preclinical experiments. The dissolution curve also shows that the bioavailability of the new formulation is likely to be higher than that of the previous BB formulation. After taking the new formulation, the API may be more effectively absorbed by the human body compared to the original formulation.
[0132] Comparison of the behavior of each candidate formulation in the three dissolution media:
[0133] For each candidate formulation, we reprocessed the same dataset to better understand and compare the dissolution behavior of each formulation in the three biorelevant media. The data are shown in Tables 12-14 and Figure 12-14 As shown:
[0134] Table 12 Dissolution data by sample (106)
[0135]
[0136] Table 13 Dissolution data by sample (112)
[0137]
[0138] Table 14 Dissolution data by sample (BB)
[0139]
[0140] Comparison of the dissolution performance of the three formulations in three media: FaSSIF (unfed intestinal fluid simulation), FeSSIF (fed intestinal fluid simulation) and FaSSGF (unfed gastric fluid simulation) Figure 12-14 By comparing the dissolution media for the same dosage form, we observed the following phenomenon: Solubility in the aqueous phase: FeSSIF (intestinal fluid after feeding) > FaSSIF (intestinal fluid without feeding) > FaSSGF (gastric fluid without feeding); the reason is probably because the intestinal fluid has a higher pH than the gastric fluid, and at the same time, it contains higher quality bile salts than the gastric fluid. In addition, the surfactant excipients added to the new formula also have the advantage of increasing solubility in water and helping the API to be better absorbed in the aqueous phase, thereby improving the bioavailability of the new formula.
[0141] The present invention improves the chemical stability of the low benzyl benzoate oral preparation formula, and can enhance the clinical and commercial application scope and use value of the formula. The high chemical stability of the formula can reduce the production cost of the product, and can also reduce the storage and transportation costs of the product, so that the product has higher economic and commercial value.
[0142] The present invention improves the bioavailability of the low benzyl benzoate oral preparation formula, can reduce the dosage of the medicine, and enhance the practicality of the medicine use for patients. The experimental results show that the solubility of the low benzyl benzoate oral preparation formula in the water phase of the dissolution experiment is 8.8 times higher than that of the original high benzyl benzoate oral preparation formula in the experiment of simulating intestinal fluid without fasting, indicating that its bioavailability is 8.8 times higher than that of the original high benzyl benzoate oral preparation formula, so that its dosage can also be 8.8 times lower than that of the original high benzyl benzoate formula, which can greatly increase the clinical and commercial application value of the low benzyl benzoate formula.
[0143] The safety of the low benzyl benzoate formula of the present invention is also greatly improved compared with the original high benzyl benzoate formula. The auxiliary materials used in the low benzyl benzoate formula meet the requirements for safe use, and the daily amount of auxiliary materials used also meets the standards and requirements for safe use. This also greatly increases the scope of use and commercial value of the low benzyl benzoate formula medicine.
Claims
1. An oral preparation containing a progestogen, characterized in that: The oral preparation consists of 10-20% by weight of 17-alpha hydroxyprogesterone caproate, 45-55% by weight of propylene glycol monocaprylate, 5-10% by weight of PEG35 castor oil, 1-6% by weight of benzyl benzoate and 20-25% by weight of propylene glycol monolaurate.
2. The oral preparation according to claim 1, which is composed of 15% by weight of 17-α hydroxyprogesterone caproate, 51.85% by weight of propylene glycol monocaprylate, 7.65% by weight of PEG35 castor oil, 4.675% by weight of benzyl benzoate, and 20.825% by weight of propylene glycol monolaurate.
3. The oral preparation according to claim 1 or 2, wherein the oral preparation is in the form of an oral liquid or a soft capsule. The oral preparation according to claim 3 , wherein the oral preparation is in the form of a soft capsule.
5. The oral preparation according to claim 1 or 2, wherein the unit preparation contains 80-150 mg of progestogen.
6. The oral preparation according to claim 3, wherein the unit preparation contains 100-120 mg of progestogen.
7. Use of the oral preparation according to any one of claims 1 to 6 in the preparation of a medicament or reagent for contraception, treatment of abortion, irregular menstruation, uterine bleeding, breast cancer or cytokine storm syndrome.
8. The method for preparing the oral preparation according to any one of claims 1 to 6, characterized in that: The method comprises the steps of weighing auxiliary materials, pre-dissolving auxiliary materials, mixing auxiliary materials, adding progestogen, and dissolving progestogen.
